Download original image
Fig. 6. MiR-4636 targeted AP1S3. (A) TargetScan ( predicted miR-4636–AP1S3 binding site. (B) Predicted binding site was validated using dual-luciferase assays, **p < 0.01 in contrast to miR-NC. (C) Binding of AP1S3 to miR-4636 was confirmed using RIP assay, **p < 0.01 in contrast to Anti-IgG. (D) AP1S3 mRNA levels in tumor and normal specimens. (E) AP1S3 mRNA levels in GES-1, RGM-1, and GC cells (HGC-27 and AGS), **p < 0.01 in contrast to GES-1. (F) Correlation between miR-4636 expression and AP1S3 expression in tumor samples was determined using Pearson’s analysis. Values are presented as mean ± SD. AP1S3, adaptor protein complex 1 sigma 3; GC, gastric cancer.
Korean J Physiol Pharmacol 2023;27:197-208
© Korean J Physiol Pharmacol